Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Change in Receivables (2023 - 2025)

Immunocore Holdings' Change in Receivables history spans 3 years, with the latest figure at -$2.0 million for Q4 2025.

  • For Q4 2025, Change in Receivables fell 253.98% year-over-year to -$2.0 million; the TTM value through Dec 2025 reached $7.3 million, down 40.59%, while the annual FY2025 figure was $7.3 million, 40.59% down from the prior year.
  • Change in Receivables for Q4 2025 was -$2.0 million at Immunocore Holdings, down from $6.0 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $10.2 million in Q4 2023 and bottomed at -$2.0 million in Q4 2025.
  • The 3-year median for Change in Receivables is $3.1 million (2023), against an average of $3.1 million.
  • The largest annual shift saw Change in Receivables skyrocketed 365.39% in 2024 before it plummeted 253.98% in 2025.
  • A 3-year view of Change in Receivables shows it stood at $10.2 million in 2023, then tumbled by 87.33% to $1.3 million in 2024, then tumbled by 253.98% to -$2.0 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Change in Receivables are -$2.0 million (Q4 2025), $6.0 million (Q3 2025), and $4.2 million (Q2 2025).